WO1998039436A3 - Compositions de muteine du facteur de croissance des fibroblastes, et procedes d'utilisation de ces compositions - Google Patents
Compositions de muteine du facteur de croissance des fibroblastes, et procedes d'utilisation de ces compositions Download PDFInfo
- Publication number
- WO1998039436A3 WO1998039436A3 PCT/JP1998/000878 JP9800878W WO9839436A3 WO 1998039436 A3 WO1998039436 A3 WO 1998039436A3 JP 9800878 W JP9800878 W JP 9800878W WO 9839436 A3 WO9839436 A3 WO 9839436A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methods
- growth factor
- fibroblast growth
- fgf
- use therefor
- Prior art date
Links
- 102000018233 Fibroblast Growth Factor Human genes 0.000 title abstract 6
- 108050007372 Fibroblast Growth Factor Proteins 0.000 title abstract 6
- 229940126864 fibroblast growth factor Drugs 0.000 title abstract 6
- 239000000203 mixture Substances 0.000 title 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 abstract 2
- 229960002897 heparin Drugs 0.000 abstract 2
- 229920000669 heparin Polymers 0.000 abstract 2
- 230000027455 binding Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
- C07K14/501—Fibroblast growth factor [FGF] acidic FGF [aFGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
- C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
L'invention décrit des mollécules d'ADN isolées qui codent des polypeptides de mutéine du facteur de croissance de fibroblaste (FCF) ainsi que les mutéines FCF codées. Les mutéines FCF présentent une activité de liaison de récepteur réduite mais gardent leur aptitude à se fixer à l'héparine. Des procédés de traitement de troubles liés à l'héparine consistent à administrer une quantité thérapeutiquement efficace d'une mutéine FCF.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4078597P | 1997-03-03 | 1997-03-03 | |
US60/040,785 | 1997-03-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1998039436A2 WO1998039436A2 (fr) | 1998-09-11 |
WO1998039436A3 true WO1998039436A3 (fr) | 1999-01-14 |
Family
ID=21912937
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1998/000878 WO1998039436A2 (fr) | 1997-03-03 | 1998-03-03 | Compositions de muteine du facteur de croissance des fibroblastes, et procedes d'utilisation de ces compositions |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO1998039436A2 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6020189A (en) | 1996-08-30 | 2000-02-01 | The Johns Hopkins University School Of Medicine | Fibroblast growth factor homologous factors (FHFs) and methods of use |
US7252818B2 (en) | 1998-07-24 | 2007-08-07 | Cardiovascular Biotherapeutics, Inc. | Method of producing biologically active human acidic fibroblast growth factor and its use in promoting angiogenesis |
AU8825601A (en) | 2000-08-15 | 2002-02-25 | Phage Biotechnology Corp | A method of producing biologically active human acidic fibroblast growth factor and its use in promoting angiogenesis |
WO2003012053A2 (fr) * | 2001-08-01 | 2003-02-13 | New York University | Identification du recepteur et des sites de liaison de l'heparine dans fgf4 par mutagenese basee sur une structure |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996022369A1 (fr) * | 1994-10-13 | 1996-07-25 | Amgen Inc. | Analogues de facteur de croissance du fibroblaste acide a stabilite et activite biologique renforcees |
WO1996038167A1 (fr) * | 1995-05-31 | 1996-12-05 | Osteosa, Inc. | Utilisation de facteurs de croissance des fibroblastes pour stimuler la croissance osseuse |
-
1998
- 1998-03-03 WO PCT/JP1998/000878 patent/WO1998039436A2/fr active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996022369A1 (fr) * | 1994-10-13 | 1996-07-25 | Amgen Inc. | Analogues de facteur de croissance du fibroblaste acide a stabilite et activite biologique renforcees |
WO1996038167A1 (fr) * | 1995-05-31 | 1996-12-05 | Osteosa, Inc. | Utilisation de facteurs de croissance des fibroblastes pour stimuler la croissance osseuse |
Non-Patent Citations (4)
Title |
---|
BURGESS, W.H., ET AL.: "possible dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic Fibroblast) growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a single lysine residue", THE JOURNAL OF CELL BIOLOGY, vol. 111, November 1990 (1990-11-01), pages 2129 - 2138, XP002074068 * |
SPRINGER, B.A., ET AL.: "identification and concerted function of two receptor binding surfaces on basic fibroblast growth factor required for mitogenesis", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 269, no. 43, October 1994 (1994-10-01), pages 26879 - 26884, XP002073992 * |
WANG W -P ET AL: "CLONING OF THE GENE CODING FOR HUMAN CLASS 1 HEPARIN-BINDING GROWTH FACTOR AND ITS EXPRESSION IN FETAL TISSUES", MOLECULAR AND CELLULAR BIOLOGY, vol. 9, no. 6, June 1989 (1989-06-01), pages 2387 - 2395, XP000039606 * |
ZHU, H., ET AL.: "Glu-96 of basic fibroblast growth factor is essential for high affinity receptor binding", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 37, September 1995 (1995-09-01), pages 21869 - 21874, XP002073993 * |
Also Published As
Publication number | Publication date |
---|---|
WO1998039436A2 (fr) | 1998-09-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2290079A3 (fr) | Facteurs neurotrophiques | |
CA2269083A1 (fr) | Homologues de facteur de croissance fibroblastes (fgf) | |
WO2001016114A3 (fr) | Composes et techniques permettant de moduler la fonction du recepteur cxcr3 | |
HK1030370A1 (en) | Compositions for treating late phase allergic reactions and inflammatory diseases, and use thereof | |
TR199802421T2 (xx) | Doku yenilenmesini d�zenleyen maddeler. | |
CA2296769A1 (fr) | Facteur modifie affectant le tissu dorsal et composition a base de ce facteur | |
CA2312667A1 (fr) | Nouvelle cytokine | |
AU5842896A (en) | Hydrotreating catalyst: composition, preparation, and use thereof | |
WO2000025725A3 (fr) | Antagonistes fonctionnels de l'activite hedgehog | |
EP0637450A3 (fr) | Méthode et composition pour revigorer le tissu cicatriciel. | |
NZ332721A (en) | Use of bactericidal/permeability increasing (BPI) protein sometimes in conjunction with a thrombolytic agent to treat thrombotic disorders | |
WO1999029729A3 (fr) | Fonction et utilisation de l'antagoniste du recepteur de la neuropiline | |
WO1999055861A3 (fr) | Compositions de muteine du facteur de croissance de fibroblastes et procedes d'utilisation associes | |
CA2233009A1 (fr) | Composition pour ameliorer la fonction pancreatique | |
AU1934995A (en) | Receptor specific atrial natriuretic peptides | |
CA2255539A1 (fr) | Utilisations therapeutiques de produits proteiques bpi chez des patients humains souffrant d'une hemorragie causee par un traumatisme | |
WO2002030357A3 (fr) | Composes et procedes servant a moduler la fonction de ccr4 | |
WO1994005791A3 (fr) | Facteur influant sur la croissance du tissu dorsal et compositions | |
HUT66309A (en) | Bpc peptides, their preparation and therapeutic use | |
WO1998039436A3 (fr) | Compositions de muteine du facteur de croissance des fibroblastes, et procedes d'utilisation de ces compositions | |
WO1999064598A3 (fr) | Nouveaux analogues de l'insuline presentant un pouvoir de liaison accru avec le zinc | |
WO1997003701A3 (fr) | Composes et methodes de traitement de cancers lies au recepteur egf et purification du recepteur egf | |
EP0373540A3 (fr) | Méthode pour purifier des facteurs de croissance protéiques de fibroblastes | |
EP0811687A3 (fr) | Polypeptides avec une activité de L-asparaginase | |
AU9487698A (en) | Methods and compositions for treating cardiac and renal disorders with atrial natriuretic peptide and tissue kallikrein gene therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 1998538364 Format of ref document f/p: F |
|
122 | Ep: pct application non-entry in european phase |